Brilinta (ticagrelor) – U.S. patent status
| Patent | Coverage | Expiration (U.S.) |
|--------|----------|-------------------|
| US 7,719,449 – “Method of using ticagrelor” | Key therapeutic patent for ticagrelor as an antiplatelet agent | 2025‑08‑22 |
| US 8,261,568 – “Ticagrelor and related compounds” | Formulation and composition of ticagrelor | 2025‑09‑12 |
| US 8,708,749 – “Ticagrelor for the prevention of thromboembolic events” | Method of using ticagrelor in clinical settings | 2025‑10‑07 |
| US 8,761,842 – “Ticagrelor derivatives and methods of use” | Derivatives and analogs | 2025‑10‑07 |
| US 9,065,203 – “Ticagrelor formulations with improved bioavailability” | New delivery systems | 2025‑12‑24 |
These dates represent the expiry of the original patents that cover the drug’s active ingredient, its therapeutic use, and certain formulation improvements in the United States. After the expiry dates, generic manufacturers may seek FDA approval, but they still have to prove bioequivalence and meet all regulatory requirements.
---
What does this mean for patients and prescribers?
1. Patent expiry does not automatically mean generics will be available.
* A generic applicant must file an Abbreviated New Drug Application (ANDA) and demonstrate that the generic product is therapeutically equivalent to Brilinta.
* Even after a patent expires, the FDA may grant a Patent Interference or Post‑Approval period, delaying market entry.
2. Brilinta remains the only brand‑name product on the market until generics clear the regulatory process.
* If a generic is approved, prices may drop substantially, potentially improving access for patients who need long‑term antiplatelet therapy.
3. Other regions have different patent timelines.
* In the European Union, the primary ticagrelor patents expire in 2028 (with some 2030 extensions depending on specific filings).
* The timeline for generic entry in Canada, Australia, and other markets varies similarly.
---
Quick summary
- U.S. patent expiration for ticagrelor (Brilinta) is 2025 (varies by specific patent, but the last major ones listed expire between August and December 2025).
- Generic entry is possible after 2025, but actual market availability depends on FDA approval.
- In the EU, the primary patents are set to expire in 2028, with some extensions to 2030.
If you need the most up‑to‑date information or details for a specific jurisdiction, let me know and I can dig into the latest filings.